Analysis of Virulence and Inflammatory Potential of Shigella flexneri Purine Biosynthesis Mutants

Infection and Immunity

Volumn 71, Issue 12, 2003, Pages 7002-7013

  Cersini, Antonella ^a   Martino, Maria Celeste ^a   Martini, Irene ^a   Rossi, Giacomo ^b   Bernardini, Maria Lina ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF CAMERINO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; NITRIC OXIDE SYNTHASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; BACTERIUM MUTANT; CARCINOMA CELL; CELL CULTURE; CONTROLLED STUDY; DEATH; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LETHAL DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PURINE SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SHIGELLA FLEXNERI; SHIGELLOSIS; VIRULENCE; WILD TYPE;

ADMINISTRATION, INTRANASAL; ANIMALS; BACTERIAL PROTEINS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; DYSENTERY, BACILLARY; FEMALE; HELA CELLS; HUMANS; INFLAMMATION; LUNG; LUNG DISEASES; MICE; MICE, INBRED BALB C; MUTATION; PURINES; SHIGELLA FLEXNERI; VIRULENCE;

EID: 0345714728     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.71.12.7002-7013.2003     Document Type: Article

References (43)

1. Ahmed, Z. U., R. S. Mahfuzur, and D. A. Sack. 1990. Protection of adult rabbits and monkeys against shigellosis by oral immunization with a thymine-requiring and temperature-sensitive mutant of Shigella flexneri Y. Vaccine 8:153-158.
2. Allaoui, A., J. Mounier, M.-C. Prévost, P. J. Sansonetti, and C. Parsot. 1992. icsB: a Shigella flexneri virulence gene necessary for the lysis of protrusions during intercellular spread. Mol. Microbiol. 6:1605-1616.
3. Altboum, Z., E. M. Barry, G. Losonsky, J. E. Galen, and M. M. Levine. 2001. Attenuated Shigella flexneri 2a ΔguaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection. Infect. Immun. 69:3150-3158.
4. Anderson, R. J., M. F. Pasetti, M. B. Sztein, M. M. Levine, and F. R. Noriega. 2000. ΔguaBA attenuated Shigella flexneri 2a strain CVD 1204 as a Shigella vaccine and as a live mucosal delivery system for fragment C of tetanus toxin. Vaccine 18:2193-2202.
5. Barry, E. M., Z. Altboum, G. Losonsky, and M. M. Levine. 2003. Immune responses elicited against multiple enterotoxigenic Escherichia coli fimbriae and mutant LT expressed in attenuated Shigella vaccine strains. Vaccine 21:333-340.
6. Bernardini, M. L., J. Arondel, I. Martini, A. Aidara, and P. J. Sansonetti. 2001. Parameters underlying successful protection with live attenuated mutants in experimental shigellosis. Infect. Immun. 69:1072-1083.
7. Bernardini, M. L., J. Mounier, H. d'Hauteville, M. Coquis-Rondon, and P. J. Sansonetti. 1989. Identification of icsA, a plasmid locus of Shigella flexneri that governs intra and intercellular spread through interaction with F-actin. Proc. Natl. Acad. Sci. USA 86:3867-3871.
8. Bullock, W. O., J. M. Fernandez, and J. M. Short. 1987. XL1-Blue: a high efficiency plasmid transforming recA Escherichia coli strain with beta-galactosidase selection. BioTechniques 5:376-378.
9. Cersini A., A. M. Salvia, and M. L. Bernardini. 1998. Intracellular multiplication and virulence of Shigella flexneri auxotrophic mutants. Infect. Immun. 66:549-557.
10. Coster, T. S., C. W. Hoge, L. L. Van De Verg, A. B. Hartman, E. V. Oaks, M. M. Venkatesan, D. Cohen, G. Robin, A. Fontaine-Thompson, P. J. Sansonetti, and T. L. Hale. 1999. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect. Immun. 67:3437-3443.
11. de Silva, D. G., L. N. Mendis, N. Sheron, G. J. M. Alexander, D. C. A. Candy, H. Chart, and B. Rowe. 1993. Concentrations of interleukin 6 and tumor necrosis factor in serum and stools of children with Shigella dysenteriae I infection. Gut 34:194-198.
12. d'Hauteville, H., S. Khan, D. J. Maskell, A. Kussak, A. Weintraub, J. Mathison, R. J. Ulevitch, N. Wuscher, C. Parsot, and P. J. Sansonetti. 2002. Two msbB genes encoding maximal acylation of lipid A are required for invasive Shigella flexneri to mediate inflammatory rupture and destruction of the intestinal epithelium. J. Immunol. 168:5240-5251.
13. Dilworth, D. D., and J. R. McCarrey. 1992. Single step elimination of contaminating DNA prior to reverse transcriptase PCR. PCR Methods Appl. 1:279-282.
14. Formal, S. B., P. Gemsky, Jr., L. S. Baron, and E. H. LaBrec. 1971. A chromosomal locus which controls the ability of Shigella flexneri to evoke keratoconjunctivitis. Infect. Immun. 3:73-79.
15. Hartman, A. B., C. Powell, C. L. Schultz, E. V. Oaks, and K. H. Eckels. 1991. Small animal model to measure efficacy and immunogenicity of Shigella vaccine strains. Infect. Immun. 59:4075-4083.
16. Hueek, C. J. 1998. Type III protein secretion systems in bacterial pathogens of animals and plants. Microbiol. Mol. Biol. Rev. 62:379-433.
17. Koprowski, H., II, M. M. Levine, R. J. Anderson, G. Losonsky, M. Pizza, and E. M. Barry. 2000. Attenuated Shigella flexneri 2a vaccine strain CVD 1204 expressing colonization factor antigen I and mutant heat-labile enterotoxin of enterotoxigenic Escherichia coli. Infect. Immun. 68:4884-4892.
18. Kotloff, K. L., F. R. Noriega, T. Samandari, M. B. Sztein, G. A. Losonsky, J. P. Nataro, W. D. Picking, E. M. Barry, and M. M. Levine. 2000. Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans. Infect. Immun. 68:1034-1039.
19. Kotloff, K. L., J. P. Winickoff, B. Ivanoff, J. D. Clemens, D. L. Swerdlow, P. J. Sansonetti, G. K. Adak, and M. M. Levine. 1999. Global burden of Shigella infections: implications for vaccine development and implementation. Bull. W. H. O. 77:651-656.
20. Lindberg, A. A., A. Karnell, B. A. D. Stocker, S. Katakura, H. Sweiha, and F. Reinholt. 1988. Development of an auxotrophic oral live Shigella flexneri vaccine. Vaccine 6:146-150.
21. Mallett, C. P., L. L. Van De Verg, H. H. Collins, and T. L. Hale. 1993. Evaluation of Shigella vaccine safety and efficacy in an intranasal challenged mouse model. Vaccine 11:190-196.
22. Mandic-Mulec, I., J. Weiss, and A. Zychlinsky. 1997. Shigella flexneri is trapped in polymorphonuclear leukocyte vacuoles and efficiently killed. Infect. Immun. 65:110-115.
23. Menard, R., P. J. Sansonetti, and C. Parsot. 1993. Nonpolar mutagenesis of the ipa genes defines IpaB, IpaC, and IpaD as effectors of Shigella flexneri entry into epithelial cells. J. Bacteriol. 175:5899-5906.
24. Miller, J. H. 1992. A short course in bacterial genetics. A laboratory manual and handbook for Escherichia coli and related bacteria. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
25. Murray, J. S., J. P. Kasselman, and T. Schountz. 1995. High-density presentation of an immunodominant minimal peptide on B cells is MHC-linked to Th1-like immunity. Cell. Immunol. 166:9-15.
26. Nathan, C., and M. U. Shiloh. 2000. Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc. Natl. Acad. Sci. USA 97:8841-8848.
27. Noriega, F. R., G. Losonsky, C. Lauderbaugh, F. M. Liao, J. Y. Wang, and M. M. Levine. 1996. Engineered ΔguaB-A ΔvirG Shigella flexneri 2a strain CVD 1205: construction, safety, immunogenicity, and potential efficacy as a mucosal vaccine. Infect. Immun. 64:3055-3061.
28. Noriega, F. R., G. Losonsky, J. Y. Wang, S. B. Formal, and M. M. Levine. 1996. Further characterization of ΔaroA ΔvirG Shigella flexneri 2A strain CVD 1203 as a mucosal Shigella vaccine and as a live-vector vaccine for delivering antigens of enterotoxigenic Escherichia coli. Infect. Immun. 64:23-27.
29. Nygaard, Y. 1983. Utilization of preformed purine bases and nucleosides, p. 27-93. In A. Munch-Petersen (ed.), Metabolism of nucleotides, nucleosides, and nucleobases in microorganisms. Academic Press, Inc., London, United Kingdom.
30. Phalipon, A., M. Kaufmann, P. Michetti, J. M. Cavaillon, M. Huerre, P. J. Sansonetti, and J. P. Kraehenbuhl. 1995. Monoclonal immunoglobulin A antibody directed against serotype-specific epitope of Shigella flexneri lipopolysaccharide protects against murine experimental shigellosis. J. Exp. Med. 182:769-778.
31. Philpott, D. J., S. Yamaoka, A. Israel, and P. J. Sansonetti. 2000. Invasive Shigella flexneri activates NF-κB through a lipopolysaccharide-dependent innate intracellular response and leads to IL-8 expression in epithelial cells. J. Immunol. 165:903-914.
32. Sansonetti, P. J., J. Arondel, J. M. Cavaillon, and M. Huerre. 1995. Role of interleukin-1 in the pathogenesis of experimental shigellosis. J. Clin. Investig. 96:884-892.
33. Sansonetti, P. J., J. Arondel, A. Fontaine, H. d'Hauteville, and M. L. Bernardini. 1991. ompB (osmo-regulation) and icsA (cell to cell spread) mutants of Shigella flexneri: vaccine candidates and probes to study the pathogenesis of shigellosis. Vaccine 9:416-422.
34. Sansonetti, P. J., J. Arondel, M. Huerre, A. Harada, and K. Matsushima. 1999. Interleukin-8 controls bacterial transepithelial translocation at the cost of epithelial destruction in experimental shigellosis. Infect. Immun. 67:1471-1480.
35. Sansonetti, P. J., A. Phalipon, J. Arondel, K. Thirumalai, S. Banerjee, S. Akira, K. Takeda, and A. Zychlinsky. 2000. Caspase-1 activation of IL-1beta and IL-18 are essential for Shigella flexneri-induced inflammation, Immunity 12:581-590.
36. Sansonetti, P. J., A. Ryter, P. Clerc, A. T. Maurelli, and J. Mounier. 1986. Multiplication of Shigella flexneri within HeLa cells: lysis of the phagocytic vacuole and plasmid-mediated contact hemolysis. Infect. Immun. 51:461-469.
37. Schwan, W. R., and D. J. Kopecko. 1997. Uptake of pathogenic intracellular bacteria into human and murine macrophages downregulates the eukaryotic 26S protease complex ATPase gene. Infect. Immun. 65:4754-4760.
38. Simon, R., U. Priefer, and A. Puhler. 1983. A broad host range mobilization system for in vivo genetic engineering: transposon mutagenesis in Gram negative bacteria. Bio/Technology 1:784-791.
39. van de Verg, L. L., C. P. Mallett, H. H. Collins, T. Larsen, C. Hammack, and T. L. Hale. 1995. Antibody and cytokine responses in a mouse pulmonary model of Shigella flexneri serotype 2a infection. Infect. Immun. 63:1947-1954.
40. Verma, N. K., and A. A. Lindberg. 1991. Construction of aromatic dependent Shigella flexneri 2a live vaccine candidate strains: deletion mutations in the aroA and the aroD genes. Vaccine 9:6-9.
41. Yoshikawa, M., C. Sasakawa, N. Okada, M. Takasaka, M. Nakayama, Y. Yoshikawa, A. Kohno, H. Danbara, H. Nariuchi, H. Shimada, and M. Toriumi. 1995. Construction and evaluation of a virG thyA double mutant of Shigella flexneri 2a as candidate live-attenuated oral vaccine. Vaccine 13:1436-1440.
42. Zychlinsky, A., K. Thirumalai, J. Arondel, J. R. Cantey, A. O. Aliprantis, and P. J. Sansonetti. 1996. In vivo apoptosis in Shigella flexneri infections. Infect. Immun. 64:5357-5365.
43. Zychlinsky, A., M. C. Prevost, and P. J. Sansonetti. 1992. Shigella flexneri induces apoptosis in infected macrophages. Nature 358:167-169.